Syn2bio (S2B) Stock Overview

A biotechnology company, engages in the research and commercialization of Cardiac Marker, a radiopharmaceutical for diagnostic testing of heart disease in the field of myocardial perfusion. More details

S2B fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap (PLN252M)

S2B Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Syn2bio S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Syn2bio
Historical stock prices
Current Share Price	zł28.85
52 Week High	zł47.40
52 Week Low	zł26.20
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-19.19%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	S2B	PL Biotechs	PL Market
7D	-0.3%	0.08%	-0.5%
1Y	n/a	-10.1%	19.0%

Return vs Industry: Insufficient data to determine how S2B performed against the Polish Biotechs industry.

Return vs Market: Insufficient data to determine how S2B performed against the Polish Market.

Price Volatility

Is S2B's price volatile compared to industry and market?
S2B volatility
S2B Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.4%
Market Average Movement	5.2%
10% most volatile stocks in PL Market	10.9%
10% least volatile stocks in PL Market	3.2%

Stable Share Price: S2B's share price has been volatile over the past 3 months compared to the Polish market.

Volatility Over Time: Insufficient data to determine S2B's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2025	n/a	Cezary Kozanecki	syn2bio.pl/en

Syn2bio S.A., a biotechnology company, engages in the research and commercialization of Cardiac Marker, a radiopharmaceutical for diagnostic testing of heart disease in the field of myocardial perfusion. The company’s flagship project is the cardiotracer project, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. Additionally, it operates The Centre for Research on New Compounds, a unit engaged in the search for new pharmaceutical compounds and their further study, registration, and market launch as a medicinal product.

Syn2bio S.A. Fundamentals Summary

How do Syn2bio's earnings and revenue compare to its market cap?
S2B fundamental statistics
Market cap	zł251.84m
Earnings (TTM)	zł0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is S2B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
S2B income statement (TTM)
Revenue	zł0
Cost of Revenue	zł0
Gross Profit	zł0
Other Expenses	zł0
Earnings	zł0

Last Reported Earnings

n/a

Next Earnings Date

Jun 25, 2026

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did S2B perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/13 02:01
End of Day Share Price	2026/05/13 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Syn2bio S.A. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Beata Szparaga-Wasniewska	Biuro maklerskie mBanku